Results 91 to 100 of about 2,891 (162)

Selinexor combined with R-GDP as salvage therapy in relapsed/refractory diffuse large B-cell lymphoma. [PDF]

Am J Cancer Res
Jiang S, Li Y, Liu C, Liu Y, Zhang Q, Lv F, Zhang W.   +6 more
europepmc   +1 more source

XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis. [PDF]

Cell Commun Signal
Xu TT, Cai MC, Cheng S, Huang YH, Zhang QQ, Xu PP, Wang L, Qiu YR, Zhao WL.   +8 more
europepmc   +1 more source

Inhibition of CRM1 reverses hypoxia-driven chemoresistance in acute myeloid leukemia via overcoming HIF-1α-mediated lysosomal sequestration. [PDF]

Front Immunol
Feng X, Ding Y, Huang Y, Qin H, Wang X, Zeng Y.   +5 more
europepmc   +1 more source

Selinexor (Xpovio™)

Oncology Times, 2020
openaire   +2 more sources

Erratum: <i>KRAS</i> under attack: recent advances in targeted therapies involving G12C inhibitors and XPO1 inhibition. [PDF]

Transl Lung Cancer Res
Editorial Office.
europepmc   +1 more source

Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer. [PDF]

Cells
Di Marco MV, Gasparetto A, Chiarle R, Voena C.   +3 more
europepmc   +1 more source

Selinexor for multiple myeloma

, 2022
openaire   +1 more source

CCT3-mediated regulation of XPO1/RB1 axis stability promotes cellular senescence and tumor progression in clear cell renal carcinoma. [PDF]

iScience
Cao Y, Xu C, Liu Y, Shi B, Li X, Li J, Zhang B, Zhang Z, Dai S, Sun Q, Gu J.   +10 more
europepmc   +1 more source

Combined XPO1 Inhibition and Parthenolide Treatment Can Be Efficacious in Treating Triple-Negative Breast Cancer. [PDF]

Int J Mol Sci
Paulson AL, Elmorsi RM, Lee AM, Huang RS.   +3 more
europepmc   +1 more source

<i>KRAS</i> under attack: recent advances in targeted therapies involving G12C inhibitors and XPO1 inhibition. [PDF]

Transl Lung Cancer Res
Falk M, Schatz S, Tiemann M, Ficker JH, Brueckl WM.   +4 more
europepmc   +1 more source